Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN ESTOLATE versus R P MYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN ESTOLATE versus R P MYCIN.
ERYTHROMYCIN ESTOLATE vs R-P MYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin estolate is a macrolide antibiotic that reversibly binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step. It may also exhibit immunomodulatory and anti-inflammatory effects.
R-P MYCIN is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, specifically at the 23S rRNA of the peptidyl transferase center. This action blocks the translocation step, thereby preventing the elongation of the peptide chain.
250-500 mg orally every 6-12 hours
Rifampin 600 mg orally once daily or 10 mg/kg intravenously once daily.
None Documented
None Documented
Approximately 1.5-2 hours in normal adults; prolonged to 5-6 hours in end-stage renal disease.
Terminal half-life 2-3 hours; prolonged in renal impairment (up to 6-8 hours in anuria).
Primarily hepatic via biliary excretion into feces; approximately 2-5% excreted unchanged in urine. <5% renal elimination.
Renal (60-80% unchanged), biliary/fecal (15-20%).
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic